MedTrace Logo

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

NCT03510767 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-14

No results posted yet for this study

Summary

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Conditions

  • Relapsed or Refractory Lymphoma or Advanced Cancer

Interventions

DRUG

TQ-B3525

TQ-B3525 p.o. qd

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huaqing Wang, doctor · People's Hospital of Tianjin Tianjin,China,300121

  • Wenqi Jiang, doctor · Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China, 510060

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-20
Primary Completion
2022-08-15
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510767 on ClinicalTrials.gov